SCHEMBL846895

SCHEMBL846895

O=C(CCc1ccccc1)c1ccc(Br)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.65
RAB9A P51151 3/20 0.65
TDP1 Q9NUW8 2/20 0.59
CASP3 P42574 1/20 0.59
SENP8 Q96LD8 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
SENP6 Q9GZR1 1/20 0.59
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
HSD11B1 P28845 1/20 0.57
DPP4 P27487 1/20 0.56
PDPK1 O15530 1/20 0.55
HSP90AA1 P07900 2/20 0.54
KEAP1 Q14145 1/20 0.53
MAPT P10636 2/20 0.53
HDAC3 O15379 1/20 0.53
ALDH1A1 P00352 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
MAPK1 P28482 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL658810 0.93 PDPK1 (0.64) NPC1RAB9ATDP1CASP3SENP8
SCHEMBL730593 0.90 GSK3B (0.57) NPC1RAB9AKMT2AMEN1HSD11B1
SCHEMBL10766281 0.89 TDP1 (0.77) NPC1RAB9ATDP1CASP3SENP8
SCHEMBL15524969 0.86 TDP1 (0.77) NPC1RAB9ATDP1CASP3SENP8
SCHEMBL28251466 0.86 TDP1 (0.77) NPC1RAB9ATDP1CASP3SENP8
SCHEMBL30572 0.86 TDP1 (0.77) NPC1RAB9ATDP1CASP3SENP8
Hydrochloric Acid SCHEMBL27556767 0.84 TDP1 (0.74) NPC1RAB9ATDP1CASP3SENP8
SCHEMBL7754574 0.83 NPC1 (0.67) NPC1RAB9ATDP1CASP3SENP8
SCHEMBL4217497 0.83 DPP4 (0.77) NPC1RAB9ATDP1CASP3SENP8
SCHEMBL8478411 0.82 DPP4 (0.66) NPC1RAB9ATDP1CASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1204636-B1 3-OXOPROPANE-1-SULPHONIC ACIDS AND SULPHONATES DSM IP ASSETS BV (NL) 2004-10-27 EP claimed
CN-111499503-B Method for synthesizing alpha-alkylated ketone in water 南京理工大学 2022-04-08 CN disclosed
CN-111499503-A Method for synthesizing α -alkylated ketone in water 南京理工大学 2020-08-07 CN disclosed
CN-106478325-B A method of synthesis alpha-alkyl ketone 南京理工大学 2019-06-25 CN disclosed
CN-106478395-B A kind of method of iridium catalyzed synthesizing alpha-alkyl ketone 南京理工大学 2019-06-25 CN disclosed
CN-105439787-B Method for synthesizing α -alkyl ketone 南京理工大学 2018-02-13 CN disclosed
CN-106478395-A A kind of method of iridium catalyzed synthesizing alpha-alkyl ketone 南京理工大学 2017-03-08 CN disclosed
CN-106478325-A A kind of method of synthesis alpha-alkyl ketone 南京理工大学 2017-03-08 CN disclosed
CN-104557500-B A kind of method of synthetic alpha-alkyl ketone NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2016-05-18 CN disclosed
CN-105439787-A Method for synthesizing alpha-alkyl ketone UNIV NANJING SCIENCE & TECH 2016-03-30 CN disclosed
EP-2308848-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor Janssen Pharmaceutica NV (BE) 2011-04-13 EP disclosed
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR CODD ELLEN 2008-12-04 US disclosed
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR CODD ELLEN 2008-12-04 US disclosed
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR CODD ELLEN 2008-12-04 US disclosed
EP-1603883-A2 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2005-12-14 EP disclosed
US-20050272036-A1 Ketones ASTRAZENECA AB (SE) 2005-12-08 US disclosed
EP-1549600-A1 KETONES AstraZeneca AB (SE) 2005-07-06 EP disclosed
US-20040192728-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2004-09-30 US disclosed
WO-2004069792-A2 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (US) 2004-08-19 WO disclosed
WO-2004011410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192728-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor TRPV1, OPRL1, TRPV2 NPC1 1518/4885RAB9A 2453/4885TDP1 4042/4885
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR TRPV1, OPRL1, TRPV2 NPC1 1518/4885RAB9A 2453/4885TDP1 4042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.